Strides Plans Injectables Re-entry As Mylan Non-Compete Nears End
Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.
You may also be interested in...
A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?
Helping to alleviate shortages of critical US injectables, including controlled substances, has strengthened Hikma’s relationships with its hospital customers in the US, including with Civica Rx, CEO Siggi Olafsson told Generics Bulletin.
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.